BLASUBCUTANEOUSINJECTIONPriority Review
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj (human recombinant)) by Johnson & Johnson. Approved for endoglycosidase [epc]. First approved in 2025.
Drug data last refreshed 22h ago
Mechanism of Action
Pharmacologic Class:
Endoglycosidase
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on RYBREVANT FASPRO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.